REFERENCES

1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913.

2. Humbert M, Sitbon O, Chaouat A, et al.

3. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30:104-109.

4. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest. 2010;137:376-387.

5. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216-223.

6. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007;30:1103-1110.

7. Pengo V Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. NEngl J Med. 2004;350:2257-2264.

8. Sahay S. Evaluation and classification of pulmonary arterial hypertension. J Thorac Dis. 2019;11:S1789-S1799.

9. Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 2019;53:1801899

10. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association—developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119:2250-2294.

11. Coghlan JG, Denton CP, Grunig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.

12. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:14S- 34S.

13. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174:1034-1041.

14. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53:1119-1126.

15. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D42-D50.

16. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161:487-492.

17. Minai OA, Pandya CM, Golish JA, et al. Predictors of nocturnal oxygen desaturation in pulmonary arterial hypertension. Chest. 2007;131:109-117.

18. van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58: 2511­2519.

19. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179:615-

621.

20. Jean-Luc Vachiery J, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019;53:1801897.

21. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:35S-62S.

22. Kim NH, Delcroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 2013;62:D92-D99.

23. Ogawa A, Satoh T, Fukuda T, et al.

24. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-Based risk assessment strategies. Chest. 2019;156:323-337.

25. Benza RL, Kanwar MK, Raina A, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL lite 2, for use in patients with pulmonary arterial hypertension. Chest. 2021; 159 337-346.

26. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50:1700889.

27. Galie N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53:1801889.

28. Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Circulation. 2014;129:57-65.

29. Preston IR, Roberts KE, Miller DP, et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation. 2015;132:2403-2411.

30. Bradley EA, Ammash N, Martinez SC, et al. “Treat-to-close”: non-repairable ASD-PAH in the adult—results from the North American ASD-PAH (NAAP) multicenter registry. Int J Cardiol. 2019;291:127-133.

31. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156-163.

32. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL).

33. American Academy Sleep Medicine Task Force. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. Sleep. 1999;22:667-689.

34. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle­aged adults. NEng J Med. 1993;328:1230-1235.

35. Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177:1006-1014.

36. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease. Circulation. 2008;118:1080-1111.

37. McNicholas WT, Bonsignore MR. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms, and research priorities. Eur Respir J. 2007;29:165- 178.

38. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep. 2008;31:1071-1078.

39. Marshall NS, Wong KKH, Liu PY, et al. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton health study. Sleep. 2008;31:1079-1085.

40. Reichmuth KJ, Austin D, Skatrud JB, Young T. Association of sleep apnea and type II diabetes: a population based study. Am J Respir Crit Care Med. 2005;172:1590-1595.

41. Karimi M, Hedner J, Habel H, et al. Sleep apnea related risks of motor vehicle accidents is reduced by continuous positive airway pressure: Swedish traffic accident registry data. Sleep. 2015;38:341-349.

42. Liistro G, Rombaux P, Belge C, et al. High Mallampati score and nasal obstruction are associated risk factors for obstructive sleep apnoea. Eur Respir J. 2003;21:248-252.

43. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13:479-504.

44. Kuan YC, Wu D, Huang KW, et al.

45. Sigurdson K, Ayas NT. The public health and safety consequences of sleep disorders. Can J Physiol Pharmacol. 2007;85:179-183.

46. Buchner NJ, Sanner BM, Borgel J, Rump LC. Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. Am J Respir Crit Care Med. 2007;176:1274-1280.

47. McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. NEngl J Med. 2016;375:919-931.

48. Fein AS, Shvilkin A, Shah D, et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol. 2013;62:300-305.

49. Borel JC, Tamisier R, Dias-Domingos S, et al. Type of mask may impact on continuous positive airway pressure adherence in apneic patients. PLoS One. 2013;8:e64382. doi:10.1371/journal.pone.0064382

50. Fietze I, Glos M, Moebus I, et al. Automatic pressure titration with APAP is as effective as manual titration with CPAP in patients with obstructive sleep apnea. Respiration. 2007;74:279-286.

51. Nussbaumer Y, Bloch K, Genser T, Thurneer R. Equivalence of autoadjusted and constant continuous positive airway pressure in home treatment of sleep apnea. Chest. 2006;129:638-643.

52. Strollo PJ, Soose RJ, Maurer JT, et al. Upper-airway stimulator for obstructive sleep apnea. N Engl J Med. 2014;370:139-149.

53. Li KK, Powell NB, Riley RW, et al. Long-term results of maxillomandibular advancement surgery. Sleep Breath. 2000;4:137-139.

54. Sher AE, Schechtman KB, Piccirillo JF. Efficacy of modifications of the upper airway in adults with obstructive sleep apnea syndrome. Sleep. 1996;19:156-177.

55. Caples SM, Rowley JA, Prinsell JR, et al. Surgical modifications of the upper airway for obstructive sleep apnea in adults: a systematic review and meta-analysis.

56. Tuomilehto HPI, Seppa JM, Partinen MM, et al. Life style intervention with weight reduction: first- line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med. 2009;179:320-327.

57. Greenberg DL, Lettieri CJ, Eliasson AH. Effects of surgical weight loss on measures of obstructive sleep apnea: a meta-analysis. Am J Med. 2009;122: 535-542.

58. Mickelson SA. Preoperative and postoperative management of obstructive sleep apnea patients. Otolaryngol Clin N Am. 2007;40:877-889.

59. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733-748.

60. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement—idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.

61. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431-440.

62. McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic SocietyJapanese Respiratory Society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management. Am J Respir Crit Care Med. 2016;194:748-761.

63. Meyer KC, Raghu G, Baughman RP. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185:1004-1014.

64. Lettieri CJ, Veerappan GR, Helman DL, et al. Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest. 2005;127:1600-1605.

65. Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63:51-58.

66. Hetzel J, Maldonado F, Ravaglia C, et al. Transbronchial cryobiopsies for the diagnosis of diffuse parenchymal lung diseases: expert statement from the Cryobiopsy Working Group on safety and utility and a call for standardization of the procedure. Respiration. 2018;95:188-200.

67. Raghu G. Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810-816.

68. Lawson WE, Loyd JE, Degryse AL. Genetics in pulmonary fibrosis—familial cases provide clues to the pathogenesis of idiopathic pulmonary fibrosis. Am J Med Sci. 2011;341:439-443.

69. Snetselaar R, van Moorsel HM, Kazemier KM, et al. Telomere length in interstitial lung diseases. Chest. 2015;148:1011-1018.

70. King TE, Jr. Idiopathic pulmonary fibrosis. In: Schwarz MI, King TE, Jr, eds. Interstitial Lung Disease. 5th ed. People's Medical Publishing House-USA; 2011:895.

71. Sheth JS, Belperio JA, Fishbein MC, et al. Utility of transbronchial vs surgical lung biopsy in the diagnosis of suspected fibrotic interstitial lung disease. Chest. 2017;151:389-399.

72. Leslie KO, Cool CD, Sporn TA, et al. Familial idiopathic interstitial pneumonia: histopathology and survival in 30 patients. Arch Pathol Lab Med. 2012;136:1366-1376.

73. Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. NEngl J Med. 2012;366:1968-1977.

74. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. NEngl JMed. 2014;370:2083-2092.

75. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. NEngl JMed. 2014;370:2071-2082.

76. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2007;132:1652-1658.

77. Nayfeh AS, Chippa V Moore DR. Nonspecific interstitial pneumonitis. In: StatPearls [Internet]. StatPearls Publishing; 2021.

78. Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Euro Resp J.

2015;46:976-987.

79. Travis WD, Hunninghake G, King TE Jr, et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008;177:1338-1347.

80. Nogueiraa R, Melo N, Novais H, et al. Hypersensitivity pneumonitis: antigen diversity and disease implications. Pulmonology. 2019;25:97-108.

81. Salisbury ML, Gu T, Murray S, et al. Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function Trajectory. Chest. 2019;155:699- 711.

82. Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2020;202:e36-e69.

83. Salisbury ML, Myers JL, Belloli EA, et al. Diagnosis and treatment of fibrotic hypersensitivity pneumonia. Where we Stand and where we need to go. Am J Respir Crit Care Med. 2017;196:690- 699.

84. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. NEngl J Med. 2019;381:1718-1727.

85. Fernandez Perez ER, Swigris JJ, Forssen AV, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest. 2013;144:1644- 1651.

86. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183:573-581.

87. Mirsaeidi M, Machado RF, Schraufnagel D, et al. Racial difference in sarcoidosis mortality in the United States. Chest. 2015;147:438-449.

88. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201:e26- e51.

89. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J. 2009;157:9-21.

90. Joint statement of the American thoracic Society (ATS), the European respiratory Society (ERS) and the world association of sarcoidosis and other granulomatous disorders (WASOG) adopted by the ATS board of Directors and by the ERS Executive Committee, February 1999. Statement on sarcoidosis. Am J Respir Crit Care Med. 1999;160:736-755.

91. Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med. 2010;104:717-723.

92. Baque-Juston M, Pellegrin A, Leroy S, et al. Organizing pneumonia: what is it? A conceptual approach and pictorial review. Diagn Interv Imaging. 2014;95:771-777.

93. Craig PH, Wells AU, Doffman S, et al. Desquamative interstitial pneumonia, respiratory bronchiolitis and their relationship to smoking. Histopathology. 2004;45:275-282.

94. Nakanishi M, Demura Y, Mizuno S, et al. Changes in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after smoking cessation. Euro Resp J. 2007;29:453-461.

95. Carrington CB, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. NEngl J Med. 1978;298:801-809.

96. Ryu JH, Colby TV, Hartman TE, Vassallo R. Smoking-related interstitial lung diseases: a concise review. Eur Respir J. 2001;17:122-132.

97. Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J. 2006;27:1272-1285.

98. Lorillon G, Tazi A. How I manage pulmonary Langerhans cell histiocytosis. Eur Respir Rev. 2017;26:170070.

99. Farzaneh MR, Jamshidiha F, Kowsarian S. Inhalational lung disease. Int J Occup Environ Med. 2010;1:11-20.

100. American thoracic Society Committee of the Scientific assembly on environmental and occupational health. Adverse effects of crystalline silica exposure. Am J Respir Crit Care Med. 1997; 155:761-768.

101. Cullinan P, Reid P. Pneumoconiosis. Prim Care Respir J. 2013;22:249-252.

102. Fireman E, Haimsky E, Noiderfer M, et al. Misdiagnosis of sarcoidosis in patients with chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:144-148.

103. Remy-Jardin M, Degreef JM, Beuscart R, et al. Coal worker's pneumoconiosis: CT assessment in exposed workers and correlation with radiographic findings. Radiology. 1990;177:363-371.

104. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246:697-722.

105. Park S, Lee EJ. Diagnosis and treatment of cystic lung disease. Korean J Intern Med. 2017;32:229-238.

106. O'Mahony AM, Lynn E, Murphy DJ, et al. Lymphangioleiomyomatosis: a clinical review. Breathe. 2020;16:200007.

107. Ryu JH, Tian X, Baqir M, Xu K. Diffuse cystic lung diseases. Front Med. 2013;7:316-327.

108. Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official American Thoracic SocietyJapanese Respiratory Society clinical practice guideline. Am J Respir Crit Care Med. 2017;196:1337-1348.

109. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595-1606.

110. Goldberg HJ, Harari S, Cottin V, et al. Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Euro Resp J. 2015;46:783-794.

111. Menko FH, van Steensel MA, Giraud S, et al. Birt-Hogg-Dube syndrome: diagnosis and management. Lancet Oncol. 2009;10:1199-1206.

112. Gupta N, Seyama K, McCormack FX. Pulmonary manifestations of Birt-Hogg-Dube syndrome. Familial Cancer. 2013;12:387-396.

113. Zamora AC, White DB, Sykes AG, et al. Amyloid-associated cystic lung disease. Chest. 2016;149:1223-1233.

114. Cha SI, Fessler MB, Cool CD, et al. Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J. 2006;28:364-369.

115. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5-13.

116. Farkas L, Gauldie J, Vbelkel NF, Kolb M. Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol. 2011;45:1-15.

117. Waxman A, Restrepo-Jaramillo R, Thnappan T, et al. Inhaled Treprostinil in pulmonary hypertension due to interstitial lung disease. NEngl JMed. 2021;384:325-334.

118. Bajwah S, Koffman J, Higginson IJ, et al. ‘I wish I knew more...' the end-of-life planning and information needs for end-stage fibrotic interstitial lung disease: views of patients, carers and health professionals. BMJ Support Palliat Care. 2013;3:84-90.

119. Corey R, Hla KM. Major and massive hemoptysis: reassessment of conservative management. Am J Med Sci. 1987;294(5):301-309.

120. Wang K, Mehta A, Turner J, eds. Flexible Bronchoscopy. 2nd ed. Wiley-Blackwell; 2004.

121. Abdulmalak C, Cottenet J, Beltramo G, et al. Haemoptysis in adults: a 5-year study using the French nationwide hospital administrative database. Eur Resp J. 2015;46:503-511.

122. Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest. 1997;112:440-444.

123. Poe RH, Israel RH, Marin MG, et al. Utility of fiberoptic bronchoscopy in patients with hemoptysis and a nonlocalizing chest roentgenogram. Chest. 1988;93:70-75.

124. Marshall TJ, Flower CDR, Jackson JE. The role of radiology in the investigation and management of patients with haemoptysis. Clin Radiol. 1996;51:391-400.

125. McGuinness G, Beacher JR, Harkin TJ, et al. Hemoptysis: prospective high-resolution CT/bronchoscopic correlation. Chest. 1994;105:1155-1162.

126. Thirumaran M, Sundar R, Sutcliffe IM, Currie DC. Is investigation of patients with haemoptysis and normal chest radiograph justified? Thorax. 2009;64:854-856.

127. Bonlokke S, Guldbrandt LM, Rasmussen TR. Bronchoscopy in patients with haemoptysis and normal computed tomography of the chest is unlikely to result in significant findings. Danish Med J. 2015;62:A5123.

128. Chalumeau-Lemoine L, Khalil A, Prigent H, et al. Impact of multidetector CT-angiography on the emergency management of severe hemoptysis. Eur J Radiol. 2013;82:e742-e747. doi:10.1016/j.ejrad.2013.07.009

129. Khalil A, Parrot A, Nedelcu C, et al. Severe hemoptysis of pulmonary arterial origin: signs and role of multidetector row CT angiography. Chest. 2008;133:212-219.

130. Saumench J, Escarrabill J, Padro L, et al. Value of fiberoptic bronchoscopy and angiography for diagnosis of the bleeding site in hemoptysis. Ann Thorac Surg. 1989;48:272-274.

131. Jackson CV Savage PJ, Quinn DL. Role of fiberoptic bronchoscopy in patients with hemoptysis and a normal chest roentgenogram. Chest. 1985;87:142-144.

132. O'Neil KM, Lazarus AA. Hemoptysis. Indications for bronchoscopy. Arch Intern Med. 1991;151:171-174.

133. Tom LM, Palevsky HI, Holsclaw DS, et al.Recurrent bleeding, survival, and longitudinal pulmonary function following bronchial artery embolization for hemoptysis in a U.S. adult population. J Vasc Interv Radiol. 2015;26:1806-1813.

134. Haponik EF, Fein A, Chin R. Managing life-threatening hemoptysis: has anything really changed. Chest. 2000;118:1431-1435.

135. Wand O, Guber E, Guber A, et al. Inhaled tranexamic acid for hemoptysis treatment: a randomized controlled trial. Chest. 2018;154:1379-1384.

136. Lordan JL, Gascoigne A, Corris PA. The pulmonary physician in critical care. Illustrative case 7: assessment and management of massive haemoptysis. Thorax. 2003;58:814-819.

137. Morice RC, Ece T, Ece F, Keus L. Endobronchial argon plasma coagulation for treatment of hemoptysis and neoplastic airway obstruction. Chest. 2001;119:781-787.

138. Tremblay A, Marquette CH. Endobronchial electrocautery and argon plasma coagulation: a practical approach. Can Respir J. 2004;11:305-310.

139. Randes JC, Schmidt E, Yung R. Occlusive endobronchial stent placement as a novel management approach to massive hemoptysis from lung cancer. J Thorac Oncol. 2008;3:1071-1072.

140. Conlan AA, Hurwitz SS. Management of massive haemoptysis with the rigid bronchoscope and cold saline lavage. Thorax. 1980;35:901-904.

141. Tsukamoto T, Sasaki H, Nakamura H. Treatment of hemoptysis patients by thrombin and fibrinogen-thrombin infusion therapy using a fiberoptic bronchoscope. Chest. 1989;96:473-476.

142. Valipour A, Kreuzer A, Koller H. Koessler W. Bronchoscopy-guided topical hemostatic tamponade therapy for the management of life-threatening hemoptysis. Chest. 2005;127:2113-2118.

143. Swanson KL, Johnson CM, Prakash UB, et al. Bronchial artery embolization: experience with 54 patients. Chest. 2002;121:789-795.

144. Brinson GM, Noone PG, Mauro MA, et al. Bronchial artery embolization for the treatment of hemoptysis in patients with cystic fibrosis. Am J Respir Crit Care Med. 1998;157:1951-1958.

145. Antonelli M, Midulla F, Tancredi G, et al. Bronchial artery embolization for the management of nonmassive hemoptysis in cystic fibrosis. Chest. 2002;121:796-801.

146. Chun HJ, Byun JY, Yoo S, et al. Added benefit of thoracic aortography after transarterial embolization in patients with hemoptysis. Am J Roentgenol. 2003;180:1577-1581.

147. Syha R, Benz T, Hetzel J, et al. Bronchial artery embolization in hemoptysis: 10-year survival and recurrence-free survival in benign and malignant etiologies—a retrospective study. RoFo. 2016;188:1061-1066.

148. Van den Heuvel MM, Els Z, Koegelenberg CF, et al. Risk factors for recurrence of haemoptysis following bronchial artery embolisation for life-threatening haemoptysis. Int J Tuberc Lung Dis. 2007;11:909-914.

149. Jean-Baptiste E. Clinical assessment and management of massive hemoptysis. Crit Care Med. 2000;28:1642-1647.

150. Bobrowitz ID, Ramakrishna S, Shim YS. Comparison of medical vs. surgical treatment of major hemoptysis. Arch Intern Med. 1983;143:1343-1346.

151. Garcia-Olive I, Sanz-Santos J, Centeno C, et al. Results of bronchial artery embolization for the treatment of hemoptysis caused by neoplasm. J Vasc Interv Radiol. 2014;25:221-228.

152. Scotet V L'Hostis C, Ferec C. The changing Epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery. Genes (Basel). 2020;11:589.

153. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2016 Annual Data Report. 2017;2018.

154. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. NEngl J Med. 2005;352:1992-2001.

155. Farrell PM, White TB, Ren CL, et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017;181S:S4-S15.

156. Parr DG, Guest PG, Reynolds JH, et al. Prevalence and impact of bronchiectasis in alpha1- antitrypsin deficiency. Am J Respir Crit Care Med. 2007;176:1215-1221.

157. Burroughs L, Woolfrey A, Shimamura A. Shwachman-Diamond syndrome: a review of the clinical presentation, molecular pathogenesis, diagnosis, and treatment. Hematol Oncol Clin N Am. 2009;23:233-248.

158. LeGrys VA, Yankaskas JR, Quittell LM, et al. Diagnostic sweat testing: the cystic fibrosis Foundation guidelines. J Pediatr. 2007;151:85-89.

159. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. NEngl JMed. 1994;331:637-642.

160. Elkins MR, Robinson M, Rose B, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. NEngl J Med. 2006;354:229-240.

161. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. NEngl J Med. 2011;365:1663-1672.

162. Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed—American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e278S-e313S. doi:10.1378/chest.12- 2359

163. Gould MK, Tang T, Liu IL, et al. Recent trends in the identification of incidental pulmonary nodules. Am J Respir Crit Care Med. 2015;192:1208-1214.

164. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. NEngl JMed. 2011;365:395-409.

165. Balekian AA, Silvestri GA, Simkovich SM, et al. Accuracy of clinicians and models for estimating the probability that a pulmonary nodule is malignant. Ann Am Thorac Soc. 2013;10:629- 635.

166. Nomori H, Watanabe K, Ohtsuka T, et al. Evaluation of F-18 Auorodeoxyglucose (FDG) PET scanning for pulmonary nodule less than 3 cm in diameter, with special reference to the CT images. Lung Cancer. 2004;45:19-27.

167. Swensen SJ, Viggiano RW, Midthun DE, et al. Lung nodule enhancement at CT: multicenter study. Radiology. 2000;214:73-80.

168. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules— when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e93s-e120s. doi:10.1378/chest.12-2351

169. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017;284:228-243.

170. Staton GW, Ingram RH. Chapter IX. Disorders of the pleura, hila, and mediastinum. In: Dale DC, Federman DD, eds. Sci Am Medicine 2004. Accessed May 3, 2005. Available at: http://edmedia.emory.edu/GStaton/Pleura,%20Hila.pdf

171. Jacoby RC, Battistella FD. Hemothorax. Semin Respir Crit Care Med. 2001;22:627-630.

172. Doerr CH, Miller DL, Ryu JH. Chylothorax. Semin Respir Crit Care Med. 2001;22:617-626.

173. Light RW A new classification of parapneumonic effusions and empyema. Chest. 1995;108:299- 301.

174. Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med. 1980;69:507-512.

175. Miller AC, Harvey JE. Guidelines for the management of spontaneous pneumothorax. Standards of care Committee, British Thoracic Society. BMJ. 1993;307:114-116.

176. Fraser RS. Pneumothorax. In: Fraser RG, Pare AJ, eds. Fraser and Pare's Diagnosis of Diseases of the Chest. 4th ed. WB Saunders; 1999:2781-2794.

177. Jantz MA, Pierson DJ. Pneumothorax and barotraumas. Clin Chest Med. 1994;15:75-91.

178. Boylan A, Broaddus VC. Tumors of the pleura. In: Mason RJ, Murray JF, Nadel JA, Broaddus VC, eds. Murray and Nadel's Textbook of Respiratory Medicine. 4th ed. Elsevier Health Sciences; 2005:1989-2010.

179. Ferrer JS, Munoz XG, Orriols RM, et al. Evolution of idiopathic pleural effusion: a prospective, long-term follow-up study. Chest. 1996;109:1508-1513.

180. Almoosa KF, Mc Cormack FX, Sahn SA. Pleural disease in lymphangioleiomyomatosis. Clin Chest Med. 2006;27:355-368.

181. Heffner JE, Brown LK, Barbieri CA. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Chest. 1997;111:970-980.

182. Sahn SA, Heffner JE. Spontaneous pneumothorax. NEngl J Med. 2000;342:868-874.

183. Sahn SA. State of the art. The pleura. Am Rev Respir Dis. 1988;138:184-234.

184. Light RW Clinical manifestations and useful tests. In: Light RW, ed. Pleural Diseases. 4th ed. Lippincott Williams and Wilkins; 2001:42-86.

185. Lee YCG, Light RW Future directions. In: Light RW, Lee YCG, eds. Textbook of Pleural Diseases. Hodder Arnold; 2003:536-541.

186. Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77:507-513.

187. Solooki M. Diagnostic yield of cytology in malignant pleural effusion: impact of volume and repeated thoracentesis. Eur Resp J. 2011;38:p3550.

188. Kennedy L, Sahn SA. Noninvasive evaluation of the patient with a pleural effusion. Chest Surg Clin NAm. 1994;4:451-465.

189. Woodring JH. Recognition of pleural effusion on supine radiographs: how much fluid is required? Am J Roentgenol. 1984;142:59-64.

190. Chen A, Massoni J, Jung D, Crippin J. Indwelling tunneled pleural catheters for the management of hepatic hydrothorax: a pilot study. Ann Am Thorac Soc. 2016;13:862-866.

191. Lois M, Noppen M. Bronchopleural fistulas. Chest. 2005;128:3955-3965.

192. Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc. 2008;83:235-250.

193. Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNAase in pleural infection. NEngl J Med. 2011;365:518-526.

194. Yeam I, Sassoon C. Hemothorax and chylothorax. Curr Opin Pulm Med. 1997;3:310-314.

195. Light RW, Broaddus VC. Pneumothorax, chylothorax, hemothorax, and fibrothorax. In: Murray RF, Nadel JA, eds. Textbook of Respiratory Medicine. 3rd ed. Elsevier Science; 2000:2043-2055.